期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

B-RafV600E突变与甲状腺乳头状癌的研究概况 被引量：2

原文传递
导出
摘要 甲状腺癌是内分泌系统最常见的恶性肿瘤［1］，近几十年发病率在持续提高。关于Braf基因突变与甲状腺乳头状癌（ papillary thyroid carcinoma，PTC）的关系，一直被诸多专家学者所关注，现综述如下。
作者 初海迪 郑海涛 姜立新
机构地区 青岛大学附属烟台毓璜顶医院骨肠外-甲状腺外科
出处 《中华内分泌外科杂志》 CAS 2015年第3期255-257,共3页 Chinese Journal of Endocrine Surgery
关键词 BRAF基因突变 甲状腺乳头状癌 CARCINOMA 内分泌系统 恶性肿瘤 甲状腺癌 年发病率 专家学者
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1Pelizzo MR, Dobrinja C, Casal Ide E, et al. The role of BRAF (V6OOE) mutation as poor prognostic factor for the outcome of pa- tients with intrathyroid papillary thyroid carcinoma [ J ]. Biomed Pharmacother,2014,68 (4) :413-417.
  • 2Mekel M, Nueera C, Hodin RA, et al. Surgical implications of B-RAFv6E mutation in fine-needle aspiration of thyroid nodules[ J]. Am J Surg,2010,200( 1 ) : 136-143.
  • 3Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitom restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation [ J ]. J Clin Invest, 2011,121 (12) :4700-4711.
  • 4Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oneogenic mutation of B-RAF [J]. Ce11,2004,116(6) :855-867.
  • 5Kleiman DA, Buitrago D, Crowley M J, et al. Thyroid stimulating hormone increase iodine uptake by thyroid cancer cells during BRAF silencing[ J]. J Surg Res,2013,182( 1 ) :85-93.
  • 6Liu D, Hu S, Han P, et al. Suppression of BRAF/MEK/MAP kl- nase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E B RAF mutant I J ]. Clin Cancer Res,2007,13 (4) : 1341-1349.
  • 7Romei C, Ciampi R, Faviana P, et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyropemxidase and sodium iodide symporter genes in papillary thyroid cancer[J]. Endocr Relat Cancer,2008,15(2) :511-520.
  • 8Zane M, Agnstini M, Enzo MV, et al. Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAFV6E: A non-in- vasive tool panel for early detection of thyroid cancer[ J]. Biomed Pharmacother,2013,67 ( 8 ) :723-730.
  • 9Porra V, Ferraro-Peyret C, Durand C, et al. Silencing of the tumor suppressor geneSLC5A8 is associated with BRAF mutations in clas- sical papillary thyroid carcinomas [ J 1. J Clin Endocrinol Metab, 2005,90 ( 5 ) : 3028-3035.
  • 10Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications [ J 1- Endocr Rev, 2007,28 (7) :742-762.

同被引文献39

  • 1Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation [ J 1. J Surg Oncol, 2004,86 ( 1 ) : 44- 54.
  • 2Ceriani L, Treglia G, Paone G, et al. Unusual muscular metasta- ses from papillary thyroid carcinoma detected by fluorine-18-fluoro- deoxyglucose PET/MRI [ J 1. J Clin Endocrino| Metab, 2013,98 (6) :2208-2209.
  • 3Milas M, Shin J, Gupta M, et al. Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples [ J ]. Ann Surg, 2010,252 ( 4 ) : 643- 651.
  • 4Matsumoto H, Sakamoto A, Fujiwara M, et al. Decreased expres- sion of the thyroid-stimulating hormone.receptor in poorly-differen- tiated carcinoma of the thyroid [ J 1. Oncol Rep, 2008,19 ( 6 ) : 1405-1411.
  • 5Xing M, Usadel H, Cohen Y, et al. Methylation of the thyroid- stimulating hormone receptor gene in epithelial thyroid tumors: amarker of malignancy and a cause of gene silencing [ J ]. Cancer Res,2003,63 (9) :2316-2321.
  • 6Khan MS, Pandith AA, Masoodi SR, et al. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status[J]. Endocrine,2014,47(2) :449-455.
  • 7Garnett M J, Marais R. Guilty as charged: B-RAF is a human on- cogene[ J]. Cancer Ce11,2004,6(4) :313-319.
  • 8Orim F, Bychkov A, Shimanmra M, et al. Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model [ J]. Thyroid,2014,24(3 ) :502-510.
  • 9Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in pa- pillary thyroid cancer and its value in tailoring initial treatment: a systematic review and recta-analysis [ J ]. Medicine ( Bahimore ) , 2012,91 (5) :274-286.
  • 10Gyftaki R, Liacos C, Politi E, et al. Differential transcriptional and protein expression of thyroid-stimulating hormone receptor in ovarian carcinomas [ J ]. Int J Gynecol Cancer, 2014,24 ( 5 ) : 851- 856.

引证文献2

二级引证文献4

中华内分泌外科杂志
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部